<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82103">
  <stage>Registered</stage>
  <submitdate>19/06/2007</submitdate>
  <approvaldate>17/08/2007</approvaldate>
  <actrnumber>ACTRN12607000415404</actrnumber>
  <trial_identification>
    <studytitle>Fish oil in knee osteoarthritis</studytitle>
    <scientifictitle>A randomized controlled trial in adults with knee osteoarthritis to determine the effect of high dose fish oil compared with low dose fish oil on symptomatic and structural outcomes.</scientifictitle>
    <utrn />
    <trialacronym>FOSTAR</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Knee osteoarthritis</healthcondition>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Osteoarthritis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Liquid oral high dose fish oil 15ml per day for duration of 2 years.</interventions>
    <comparator>Liquid oral oil 15ml/day (which contains fish oil 2ml plus 13ml canola oil per day) for duration of 2 years.</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: Other</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in pain scale of WOMAC index</outcome>
      <timepoint>At 3,6,12, 18 and 24 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in knee MRI cartilage volume and defect score</outcome>
      <timepoint>At 24 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change in disability scale of WOMAC index</outcome>
      <timepoint>At 3,6,12, 18 and 24 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>OMERACT-OARSI responder criteria</outcome>
      <timepoint>At 3,6,12, 18 and 24 months.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Analgesic use</outcome>
      <timepoint>At 3,6,12, 18 and 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in quality of life using Australian Quality of Life (AQOL) questionnaire</outcome>
      <timepoint>At 3,6,12, 18 and 24 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change in MRI scores of synovitis and bone oedema</outcome>
      <timepoint>From baseline to 24 months.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Adults with symptomatic knee osteoarthritis, defined using American College of Rheumatology (ACR) criteria. Symptomatic knee osteoarthritis (score of &gt;4 on at least 1 pain dimension of the Western Ontario and McMaster Osteoarthritis Index (WOMAC).</inclusivecriteria>
    <inclusiveminage>40</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>-2147483648</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Dementia or inability to give informed consent; grade 4 (endstage) xray changes in the symptomatic knee; planned knee joint replacement surgery; daily fish oil ingestion &gt;=10mL or 9 standard capsules for the preceding 3 months; contra-indications to MRI.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central pharmacy allocation</concealment>
    <sequence>Computerised sequence generation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Subject-blinded, clinician-blinded, assessor blinded</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/07/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>National Health and Medical Research Council (NHMRC)</primarysponsorname>
    <primarysponsoraddress>Level 5, 20 Allara Street
Canberra ACT 2601</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council (NHMRC) Project Grant 451900</fundingname>
      <fundingaddress>Canberra</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council</fundingname>
      <fundingaddress>Level 5, 20 Allara Street
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>N/A</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of this study is to assess the efficacy of an anti-inflammatory dose of fish oil in the treatment of knee osteoarthritis, both with regard to symptom control and progression of structural changes. These will be assessed using WOMAC questionnaire, analgesic use and knee magnetic resonance imaging (MRI).</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Queen Elizabeth Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>29/01/2007</ethicapprovaldate>
      <hrec>2006170</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Adelaide Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Catherine Hill</name>
      <address>Rheumatology Unit
The Queen Elizabeth Hospital
28 Woodville Road
Woodville SA 5011</address>
      <phone>+61 8 82226691</phone>
      <fax>+61 8 82227156</fax>
      <email>Catherine.Hill@nwahs.sa.gov.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ruth Battersby</name>
      <address>Rheumatology Unit
The Queen Elizabeth Hospital
28 Woodville Road
Woodville SA 5011</address>
      <phone>+61 8 82227367</phone>
      <fax>+61 8 82227156</fax>
      <email>ruth.battersby@health.sa.gov.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Catherine Hill</name>
      <address>Rheumatology Unit
The Queen Elizabeth Hospital
28 Woodville Road
Woodville SA 5011</address>
      <phone>+61 8 82226691</phone>
      <fax>+618 82227156</fax>
      <email>Catherine.Hill@nwahs.sa.gov.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>